UBS O'Connor’s Neurocrine Biosciences NBIX Stock Holding History

UBS O'Connor’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$85K	–	572
2023 Q4	$85K	Buy	+10,000	New	+$1.15M	﹤0.01%	416

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS O'Connor's NBIX Position: Q1 2025 in Review

UBS O'Connor sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 23,111 shares — an estimated $3.15M sold.

UBS O'Connor first reported a position in NBIX in Q3 2013 and held it in 16 quarters. The position peaked at $4.49M in Q1 2016. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

UBS O'Connor reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 23,111 Neurocrine Biosciences shares in Q1 2025, an estimated $3.15M.
UBS O'Connor first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 16 quarters.
UBS O'Connor's Neurocrine Biosciences position peaked at $4.49M in Q1 2016.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.